UCB Reports the Commercial Availability of Rystiggo (rozanolixizumab-noli) for Adult Patients with Generalized Myasthenia Gravis in the US
Shots:
- The company launched Rystiggo in the US for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) Ab+
- The company also provides a personalized patient support program ONWARD which is available to eligible patients and caregivers to provide support during treatment with UCB rare disease medicines, incl. Rystiggo
- Rystiggo, the first US FDA-approved targeted treatment for anti-AChR Ab+ and anti-MuSK Ab+ adults with gMG1 and an HCP-administered inj. or SC use. In order to support eligible patients with administration in the home setting, UCB has worked with a limited network of specialized pharmacies with home infusion capabilities
Ref: UCB | Image: UCB
Related News:- UCB’s Rystiggo (rozanolixizumab) Receives the US FDA’s Approval for the Treatment of Adults with Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
